Promotions & Moves

TCR2 Therapeutics Expands Leadership Team

Aims to support clinical trials with an emphasis on manufacturing, IND enablement and development of next generation of TRuC-T cells

TCR2 Therapeutics Inc. announced an expansion of its leadership team to strengthen expertise in manufacturing, Investigational New Drug (IND) enablement and innovation as the Company advances its approach of creating next generation TRuCTM-T cells addressing the tumor microenvironment.   Robert Tighe joins TCR2 as Vice President of Translational Research. Previously, he served as Vice President of Translational Immunology and Immunopharmacology at Compass Therapeutics, where he led the discove...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters